GB1603597A - Method of producing a vaccine for use in the immunotherapy of neoplastic disease - Google Patents
Method of producing a vaccine for use in the immunotherapy of neoplastic disease Download PDFInfo
- Publication number
- GB1603597A GB1603597A GB21668/78A GB2166878A GB1603597A GB 1603597 A GB1603597 A GB 1603597A GB 21668/78 A GB21668/78 A GB 21668/78A GB 2166878 A GB2166878 A GB 2166878A GB 1603597 A GB1603597 A GB 1603597A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer
- cells
- vaccine
- antigens
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title claims description 38
- 238000000034 method Methods 0.000 title claims description 20
- 238000009169 immunotherapy Methods 0.000 title claims description 16
- 201000010099 disease Diseases 0.000 title claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 15
- 230000001613 neoplastic effect Effects 0.000 title claims description 11
- 239000003708 ampul Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 125
- 206010028980 Neoplasm Diseases 0.000 description 115
- 201000011510 cancer Diseases 0.000 description 108
- 239000000427 antigen Substances 0.000 description 89
- 108091007433 antigens Proteins 0.000 description 89
- 102000036639 antigens Human genes 0.000 description 89
- 230000028993 immune response Effects 0.000 description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 239000000499 gel Substances 0.000 description 19
- 230000001900 immune effect Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000001226 triphosphate Substances 0.000 description 12
- 235000011178 triphosphate Nutrition 0.000 description 12
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 11
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 239000011572 manganese Substances 0.000 description 8
- 229910052748 manganese Inorganic materials 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 210000003850 cellular structure Anatomy 0.000 description 5
- -1 i.e. Proteins 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 4
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000011565 manganese chloride Substances 0.000 description 4
- 235000002867 manganese chloride Nutrition 0.000 description 4
- IPJKJLXEVHOKSE-UHFFFAOYSA-L manganese dihydroxide Chemical compound [OH-].[OH-].[Mn+2] IPJKJLXEVHOKSE-UHFFFAOYSA-L 0.000 description 4
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- SZINCDDYCOIOJQ-UHFFFAOYSA-L manganese(2+);octadecanoate Chemical compound [Mn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O SZINCDDYCOIOJQ-UHFFFAOYSA-L 0.000 description 1
- 229910000158 manganese(II) phosphate Inorganic materials 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89812278A | 1978-04-20 | 1978-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1603597A true GB1603597A (en) | 1981-11-25 |
Family
ID=25408978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB21668/78A Expired GB1603597A (en) | 1978-04-20 | 1978-05-23 | Method of producing a vaccine for use in the immunotherapy of neoplastic disease |
Country Status (11)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2144330A (en) * | 1983-08-04 | 1985-03-06 | Nat Res Dev | Immunological compositions |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2900184A (en) * | 1983-06-10 | 1984-12-13 | Richard F. Martin | Membrane antigens generated from pooled cells and monoclonal antibodies |
| DE19519492A1 (de) * | 1995-05-27 | 1996-11-28 | Miele & Cie | Tragvorrichtung für metallische Werkstücke |
| CN1100569C (zh) * | 1997-01-24 | 2003-02-05 | 石桂秀 | 肿瘤疫苗制备方法 |
| EP4025245A1 (en) * | 2019-09-04 | 2022-07-13 | VCell Therapeutics, Inc. | Vaccine for treatment of cancer and method of making by stress reprogramming |
| WO2025028658A1 (ja) * | 2023-08-03 | 2025-02-06 | 国立大学法人東京農工大学 | 免疫増強剤及び免疫増強方法並びにタンパク質の凝集体及び／又は会合体の製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065141A (en) * | 1960-08-24 | 1962-11-20 | Albert E Gessler | Separation of nucleoproteins and nucleic acids from aqueous protein mixtures |
| DE1617865A1 (de) * | 1966-03-12 | 1971-09-02 | Karl Dr Med Theurer | Verfahren zur Herstellung von Arzneimitteln gegen Krebs |
| GB1193378A (en) * | 1967-04-11 | 1970-05-28 | Rand Dev Corp | Cancer Antigen Complexes |
| GB1291134A (en) * | 1970-01-21 | 1972-09-27 | Anvar | A process for the production of mammal cell anti-sera |
| US4053586A (en) * | 1971-10-08 | 1977-10-11 | Intermountain Laboratories, Inc. | Preparation for treating squamous cell carcinoma and method for making same |
| ZA782613B (en) * | 1978-05-08 | 1979-12-27 | D Mccollester | Vaccine and method for immunotherapy of neoplastic disease |
-
1978
- 1978-05-11 IN IN358/DEL/78A patent/IN149012B/en unknown
- 1978-05-11 AU AU36059/78A patent/AU519008B2/en not_active Expired
- 1978-05-12 MX MX787089U patent/MX5759E/es unknown
- 1978-05-15 IE IE974/78A patent/IE47736B1/en unknown
- 1978-05-21 PH PH21185A patent/PH14990A/en unknown
- 1978-05-22 NL NL7805501A patent/NL7805501A/xx unknown
- 1978-05-23 GB GB21668/78A patent/GB1603597A/en not_active Expired
- 1978-05-24 JP JP6116378A patent/JPS54154506A/ja active Pending
- 1978-05-24 FR FR7815458A patent/FR2423223A1/fr active Granted
- 1978-05-24 DE DE19782822731 patent/DE2822731A1/de not_active Withdrawn
- 1978-05-24 BE BE187981A patent/BE867410A/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2144330A (en) * | 1983-08-04 | 1985-03-06 | Nat Res Dev | Immunological compositions |
| US4661346A (en) * | 1983-08-04 | 1987-04-28 | National Research Development Corporation | Immunological compositions including a peptide and osmium or ruthenium tetroxide |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3605978A (en) | 1979-11-15 |
| MX5759E (es) | 1984-06-28 |
| DE2822731A1 (de) | 1979-10-31 |
| NL7805501A (nl) | 1979-10-23 |
| IN149012B (enrdf_load_stackoverflow) | 1981-08-15 |
| PH14990A (en) | 1982-03-12 |
| FR2423223B1 (enrdf_load_stackoverflow) | 1983-07-29 |
| JPS54154506A (en) | 1979-12-05 |
| AU519008B2 (en) | 1981-11-05 |
| FR2423223A1 (fr) | 1979-11-16 |
| IE47736B1 (en) | 1984-06-13 |
| IE780974L (en) | 1979-10-20 |
| BE867410A (fr) | 1978-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4720386A (en) | Vaccine and method for immunotherapy of neoplastic disease | |
| Nicholson-Weller et al. | Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b, 2a. | |
| Alexander et al. | Effect of nucleic acids from immune lymphocytes on rat sarcomata | |
| Evans et al. | Mechanisms of extracellular killing of nucleated mammalian cells by macrophages | |
| Cooper et al. | The role of antibody and complement in the control of viral infections | |
| Tyler | The manipulations of macromolecular substances during fertilization and early development of animal eggs | |
| GB1603597A (en) | Method of producing a vaccine for use in the immunotherapy of neoplastic disease | |
| Cavelti | Autoimmunologic disease | |
| EP0853486A2 (en) | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases | |
| MARSH et al. | Immunologic aspects of osteosarcoma and their application to therapy: a preliminary report | |
| Anderson | Hemolysins and hemagglutinins in the coelomic fluid of a polychaete annelid. Glycera dibranchiata | |
| Rickard | Hypothesis for the long term survival of Taenia pisiformis cysticerci in rabbits | |
| Schriber et al. | Induction of blood eosinophilia by pulmonary embolization of antigen-coated particles: the relationship to cell-mediated immunity | |
| JPH03117486A (ja) | 動物細胞膜に蛋白質を挿入する方法 | |
| Sonozaki et al. | The macrophage disappearance reaction: II. Mediation by lymphocytes which lack complement receptors | |
| US4076701A (en) | Tumor complement fraction recovery method and product | |
| US4001080A (en) | Production of immunological materials | |
| Allgöwer et al. | Burn sepsis and burn toxin | |
| GB1592496A (en) | Method of producing vaccine for the immunotherapy of neoplastic disease | |
| EP0101505B1 (en) | Method for the purification of parasite antigenic factors | |
| CA1102696A (en) | Vaccine and method for immunotherapy of neoplastic disease | |
| Gengozian et al. | Abnormal immune mechanism in allogeneic radiation chimeras | |
| Shupe et al. | Stimulated chemotactic response in neutrophils from Trichinella pseudospiralis-infected mice and the neutrophilotactic potential of Trichinella extracts | |
| Rosenfeld et al. | Transfer factor: a subcellular component that transmits information for specific immune responses | |
| Skornick et al. | Induction of delayed hypersensitivity reactions in cancer patients by cholesterol hemisuccinate-treated autologous tumor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] |